Product Description
DB-1419 is a bispecific antibody-drug conjugate targeting B7H3 and PD-L1. It was discovered by Duality Biologics and is still in the preclinical stage according to the pipeline on the official website. In 2022 and 2023, Duality Biologics filed patents (WO2024140846) covering anti-B7H3xPD-L1 BsAb ADCs. The patent includes examples of bispecific antibody-drug conjugates comprising the following components: an anti-B7H3 and PD-L1 bispecific antibody or an antigen-binding fragment thereof, a linker unit L, and TOP1 inhibitor, with a drug-to-antibody ratio (DAR) of 4, 6, or 8. (Sourced from: https://www.cnbio.xyz/2024/08/dualitybio-has-initiated-trial-of-db-1419.html?m=1)
Mechanisms of Action: B7-H3 Inhibitor,PD-L1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: DualityBio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|